heptapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-27. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
=== Pundits === Frank Chodorov (1907), conservative activist, founder of the Intercollegiate Studies Institute, editor of The Freeman Arnold Beichman (1934), conservative critic Ralph de Toledano (1938), conservative commentator, editor of National Review and Newsweek Joseph Kraft (1947), political columnist, speechwriter for John F. Kennedy Jules Witcover (1949), columnist, The Baltimore Sun Norman Podhoretz (1950), a "father of neoconservatism", editor of Commentary Magazine and author of Making It Jeffrey Hart (1952), conservative cultural critic and advisor to the Dartmouth Review David Horowitz (1959), conservative commentator and activist; author of the Academic Bill of Rights Herbert London (1960), conservative activist; former professor at New York University and first dean of the Gallatin School of Individualized Study; former president of conservative think tank Hudson Institute D. Keith Mano (1963), conservative political commentator for National Review Lawrence Auster (1971), Traditionalist conservative blogger and essayist Andrew Levy (1988), conservative commentator and host of Red Eye on Fox News
=== Ischemia and hypoxia === Blood vessels constrict in tissue that becomes cold and dilate in warm tissue, altering blood flow to the area. Thus keeping the tissues warm is probably necessary to fight both infection and ischemia. Some healthcare professionals use 'radiant bandages' to keep the area warm, and care must be taken during surgery to prevent hypothermia, which increases rates of post-surgical infection. Underlying ischemia may also be treated surgically by arterial revascularization, for example in diabetic ulcers, and patients with venous ulcers may undergo surgery to correct vein dysfunction. Diabetics that are not candidates for surgery (and others) may also have their tissue oxygenation increased by Hyperbaric Oxygen Therapy, or HBOT, which may provide a short-term improvement in healing by improving the oxygenated blood supply to the wound. In addition to killing bacteria, higher oxygen content in tissues speeds growth factor production, fibroblast growth, and angiogenesis. However, increased oxygen levels also means increased production of ROS. Antioxidants, molecules that can lose an electron to free radicals without themselves becoming radicals, can lower levels of oxidants in the body and have been used with some success in wound healing. Low level laser therapy has been repeatedly shown to significantly reduce the size and severity of diabetic ulcers as well as other pressure ulcers. Pressure wounds are often the result of local ischemia from the increased pressure.
Smoking, involves burning and inhaling cannabinoids ("smoke") from small pipes, bongs (portable versions of hookahs with a water chamber), paper-wrapped joints, tobacco-leaf-wrapped blunts, or the like. Vaporizing, heating various forms of cannabis to 165–190 °C (329–374 °F), causing the active ingredients to form vapor without combustion of the plant material (the boiling point of THC is 157 °C (315 °F) at atmospheric pressure). Edibles, adding cannabis as an ingredient to a wide variety of foods, including butter and baked goods. In India it is commonly consumed as the beverage bhang. Cannabis tea, prepared with attention to the lipophilic quality of THC, which is only slightly water-soluble (2.8 mg per liter), often involving cannabis in a saturated fat. Tincture of cannabis, sometimes known as green dragon, is an alcoholic cannabis concentrate. Capsules, typically containing cannabis oil, and other dietary supplement products, for which some 220 were approved in Canada in 2018.
=== Books and book chapters === Bhatt is the Editor of the first and second editions of Cardiovascular Intervention: A Companion to Braunwald's Heart Disease and of Opie's Cardiovascular Drugs: A Companion to Braunwald's Heart Disease. He is one of the co-editors of Braunwald's Heart Disease. Elsevier credits him with a total of 11 titles as an author, chapter contributor, and editor.
Sources: en.wikipedia.org
==== Austria ==== The highest radon concentrations in Austria were measured in 1991 in the municipality of Umhausen in Tyrol. Umhausen has about 2300 inhabitants and is located in the Ötztal valley. Some of the houses there were built on a bedrock of granite gneiss. From this porous subsoil, the radon present in the rock seeped freely into the unsealed cellars, which were contaminated with up to 60,000 Becquerels of radon per cubic meter of air. Radon levels in the apartments in Umhausen have been systematically monitored since 1992. Since then, extensive radon mitigation measures have been implemented in the buildings: New buildings, sealing of cellar floors, forced ventilation of cellars or relocation. Queries in the Austrian Health Information System (ÖGIS) have shown that the incidence of new cases of lung cancer has declined sharply since then. The Austrian National Radon Project (ÖNRAP) has studied radon exposure throughout the country. Austria also has a Radiation Protection Act as a legal basis. Indoor limits were set in 2008 The Austrian Ministry of the Environment states that
Parmotrema perlatum has a thallus that ranges from loosely to tightly attached to the surface it grows on, forming expansive, spreading colonies that often merge together. Individual thalli typically measure up to 10–15 cm (4–6 in) in diameter. The upper thallus surface is greenish-grey, blue-grey, or yellowish-grey in colour, lacking pruina and either free of spots (maculae), or with few maculae. This species develops soredia, a type of asexual reproductive structure, aiding in its propagation. The lobes of this lichen vary from 1.5 to 10 mm in width, with a wave-like (undulate) or ruffled pattern and overlapping (imbricate) arrangement. The tips and edges of these lobes are generally smooth and round, sometimes notched (crenate) or incised, often curling up or inward, revealing the paler brown to black underside adorned with hair-like structures (cilia) up to 2.5 mm in length. Rhizines are common on the underside of the thallus, except for a brown border near the edges. The soredia found in this species are granular and appear white or may become grey due to wear. They are located within specifically structured groups called soralia, which can be linear to oval in shape, often positioned at the edges of the lobes. The presence of soredia causes the lobe margins to curl back and form capitate soralia. The upper surface of the lichen is typically whitish grey to pale greenish-grey, and can be either smooth or slightly wrinkled, without spots (immaculate), featuring scattered, shallow cracks. Isidia are absent in this species.
=== Road freight === Transport by road is by far the most popular means of moving freight around South Africa. As of October 2025, over 85% of land freight in SA travels by road. For every ton of freight moved by rail, more than six tons is moved by road. Each year, almost 1 billion tons (984 million) of freight is transported along South Africa's road networks. This is an increase of over 50% over the period between 2010 and 2025. National roads in South Africa are administered by SANRAL, a state-owned company that reports to the Department of Transport. SANRAL is responsible for financing, managing, planning, developing, and maintaining the national road network. Municipalities also have control over and put funding into certain roadways. Certain avenues of private funding for roadways in South Africa also exist.
Sources: en.wikipedia.org
sequence logo In bioinformatics, a graphical representation of the conservation of nucleobases or amino acids at each position within a nucleic acid or protein sequence. Sequence logos are created by aligning many sequences and used to depict consensus sequences as well as the degree of variability within the pool of aligned sequences.
Zverev then made only modest achievements in the succeeding weeks, losing to Learner Tien in the second round of the Mexican Open, to Tallon Griekspoor in the second round of Indian Wells, to Arthur Fils in the fourth round of the Miami Open, and to Matteo Berrettini in Monte-Carlo. In April, Zverev won his 3rd title in Munich and 24th overall on his birthday, winning in straight sets over Ben Shelton. Zverev was presented his trophy BMW by Dominic Thiem, and reclaimed the world No. 2 ranking from Alcaraz. The next week, he reached the round of 16 at the Madrid Open. During his third round match, Zverev was given a code violation for taking a photo of the ball mark of shot which Zverev considered to have been erroneously called in. Later, social media posts from the ATP Tour suggested that the Hawk-Eye call was correct and that Zverev likely took a picture of a different mark. Following this, Zverev failed to defend either his titles in Rome and Hamburg with a straight sets loss against an in-form Lorenzo Musetti and a three-set loss against Alexandre Müller, respectively. At the French Open where he was defending finalist points, Zverev advanced to the quarterfinals, where he was defeated by Novak Djokovic in a four-set match. On the grass, Zverev reached his third final of the year in Stuttgart, losing to Taylor Fritz in straight sets in his fifth consecutive loss against the American. He then reached the semifinals against Daniil Medvedev in Halle, losing in three sets.
=== Other and unspecified disorders of metabolism === 277 Other and unspecified disorders of metabolism 277.0 Cystic fibrosis 277.1 Disorders of porphyrin metabolism Porphyria Acute intermittent porphyria 277.2 Other disorders of purine and pyrimidine metabolism Lesch–Nyhan syndrome Purine nucleoside phosphorylase deficiency Xanthinuria 277.3 Amyloidosis Familial Mediterranean fever 277.4 Hyperbilirubinemia Crigler–Najjar syndrome Gilbert's syndrome 277.5 Mucopolysaccharidosis Hunter syndrome Hurler syndrome Morquio–Brailsford disease Sanfilippo syndrome 277.6 Other deficiencies of circulating enzymes Alpha 1-antitrypsin deficiency Biotinidase deficiency Hereditary angioedema 277.7 Dysmetabolic syndrome X Metabolic syndrome 277.8 Other specified disorders of metabolism 277.81 Primary carnitine deficiency 277.82 Carnitine deficiency due to inborn errors of metabolism 277.83 Iatrogenic carnitine deficiency 277.84 Other secondary carnitine deficiency 277.85 Disorders of fatty acid oxidation metabolism Carnitine palmitoyltransferase I deficiency Carnitine palmitoyltransferase II deficiency Very long-chain acyl-coenzyme A dehydrogenase deficiency Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency Medium-chain acyl-coenzyme A dehydrogenase deficiency 277.86 Disorders of peroxisomal metabolism Zellweger syndrome 277.87 Disorders of mitochondrial metabolism Kearns–Sayre syndrome Mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS syndrome) Mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE) Myoclonus with epilepsy and with ragged red fibers (MERRF syndrome) Neuropathy, ataxia, and retinitis pigmentosa (NARP syndrome) 277.88 Tumor lysis syndrome 277.89 Other specified disorders of metabolism
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.